Clinical Trial

Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The main purpose of the study is to evaluate the safety, tolerability and recommended dose of PM54 in combination with pembrolizumab. To assess the antitumor activity of PM54 in combination with pembrolizumab in terms of clinical benefit rate (CBR) and objective response rate (ORR) based on investigator's assessment in participants in other cohorts.
Protocol Amendment History 1 change
notable Trial sites expanded: 6 -> 11 locations 2026-07-31
Trial Details
NCT Number NCT07644039
Lead Sponsor PharmaMar
Conditions Advanced Malignancies
Enrollment 119 participants
Start Date 2026-05-21
Primary Completion 2029-04-02 (estimated)
Study Completion 2029-04-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-30